We have also found reduced TET2 expression levels in PAH patients compared to controls and demonstrated that mutations in TET2 promote an inflammatory form of PAH in patients, characterized by an increase in circulating levels of inflammatory cytokines, including IL-6 and IL-1β (Figure 6A–C) [20]. Here, IL6 is linked to pulmonary arterial hypertension.